The interventions also reduced plasma FGF21 (p = 0.0030), IL‐6 (p = 0.0101), IL‐8 (p = 0.0087), IL‐10 (p < 0.0001), and IL‐18 (p = 0.0009) irrespective of training modality or T2D status. The gene discussed is CXCL8; the disease is type 2 diabetes mellitus.